Your browser doesn't support javascript.
loading
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Meulendijks, Didier; Henricks, Linda M; Jacobs, Bart A W; Aliev, Abidin; Deenen, Maarten J; de Vries, Niels; Rosing, Hilde; van Werkhoven, Erik; de Boer, Anthonius; Beijnen, Jos H; Mandigers, Caroline M P W; Soesan, Marcel; Cats, Annemieke; Schellens, Jan H M.
Afiliação
  • Meulendijks D; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
  • Henricks LM; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
  • Jacobs BAW; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
  • Aliev A; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
  • Deenen MJ; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
  • de Vries N; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
  • Rosing H; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
  • van Werkhoven E; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
  • de Boer A; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
  • Beijnen JH; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 EC The Netherlands.
  • Mandigers CMPW; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 EC The Netherlands.
  • Soesan M; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
  • Cats A; Faculty of Science, Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands.
  • Schellens JHM; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
Br J Cancer ; 116(11): 1415-1424, 2017 May 23.
Article em En | MEDLINE | ID: mdl-28427087
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Timidilato Sintase / Uracila / Di-Hidrouracila Desidrogenase (NADP) / Capecitabina / Fluoruracila / Neoplasias / Antimetabólitos Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Timidilato Sintase / Uracila / Di-Hidrouracila Desidrogenase (NADP) / Capecitabina / Fluoruracila / Neoplasias / Antimetabólitos Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article